{
  "docId": "019de076-928b-754c-8bda-49c7fed3154d",
  "docSlug": "58a8f830d3c9f9a6fedd64a0d2a10227",
  "documentTitle": "ATAI | Investor Presentation Deck | 34 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 34,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a line chart to show longitudinal changes in HCQ-29 subscales across three time points (Pre-dose, Discharge, 1 Month).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-928b-754c-8bda-49c7fed3154d/22",
  "deckHref": "/decks/019de076-928b-754c-8bda-49c7fed3154d",
  "deckJsonHref": "/decks/019de076-928b-754c-8bda-49c7fed3154d.json",
  "deckAnchorHref": "/decks/019de076-928b-754c-8bda-49c7fed3154d#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Self-reported dimensions of craving",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bde730a0-26c8-40b8-9ec9-1e319b9a56c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.4,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "list",
      "text": "1. Summary: A single-dose of ibogaine showed reductions in self-reported opioid cravings in 74 opioid dependent patients. 2. Efficacy - Relapse Prevention: Opioid dependent patients had significant reductions in the mean scores of four HCQ-29 domains... 3. Efficacy - Post-Acute Withdrawal Syndrome: signs and symptoms at post dose assessments were reduced... 4. Safety: Ibogaine was reported to be well tolerated with no serious adverse events.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da13cfcf-9879-46fa-bc34-4fdf4b2e1e5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.94,
        "x": 0.03,
        "y": 0.1
      },
      "kind": "paragraph",
      "text": "Results from an open-label study of 8-12 mg/kg of ibogaine in patients seeking detoxification from opioids and cocaine",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c18aa471-4028-4094-b002-26399e962b8f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: TRD = Treatment Resistant Depression; DMT = N,N-Dimethyltryptamine. 1 Mash et al., “Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes” (2018)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2e9ab9c-9996-45d3-bcb0-e97ac568a50f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.94,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Clinical Evidence: Efficacy of ibogaine in Open-Label Safety and Efficacy Study",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5564c29d-97d7-423f-9de7-2a0e48874423",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 34,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "c65cfc1b-596e-44b3-abf6-776a6539dcbf",
      "evidence": "The deck emphasizes the need for effective treatments",
      "position": 0,
      "objective": "Highlight the importance of addressing mental health disorders",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 34,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "7657d45c-02c7-40ab-9afc-a644dc2ed2c5",
      "evidence": "The deck follows a structure that aligns with the Golden Circle",
      "position": 1,
      "objective": "Explain the company's approach and solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}